BlackRock
AVBP icon

BlackRock’s ArriVent BioPharma AVBP Stock Holding History

BlackRock’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113M Buy
3,250,396
+720,095
+28% +$21.3M ﹤0.01% 2156
2026
Q1 		$58.4M Buy
2,530,301
+157,463
+7% +$3.56M ﹤0.01% 2411
2025
Q4 		$47.7M Buy
2,372,838
+326,700
+16% +$6.8M ﹤0.01% 2544
2025
Q3 		$37.8M Buy
2,046,138
+207,762
+11% +$4.08M ﹤0.01% 2680
2025
Q2 		$40M Sell
1,838,376
-301,412
-14% -$6.26M ﹤0.01% 2584
2025
Q1 		$39.6M Buy
2,139,788
+4,696
+0.2% +$115K ﹤0.01% 2501
2024
Q4 		$56.9M Buy
2,135,092
+203,673
+11% +$5.85M ﹤0.01% 2379
2024
Q3 		$45.4M Buy
1,931,419
+1,268,154
+191% +$28.8M ﹤0.01% 2522
2024
Q2 		$12.3M Buy
663,265
+8,461
+1% +$151K ﹤0.01% 3255
2024
Q1 		$11.7M Buy
+654,804
New +$13.2M ﹤0.01% 3269

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock's AVBP Position: Q2 2026 in Review

BlackRock increased its ArriVent BioPharma (AVBP) stake by 28% in Q2 2026, buying an estimated $21.3M and bringing the position to 3,250,396 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #2156.

BlackRock first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • BlackRock held 3,250,396 shares of ArriVent BioPharma worth $113M as of Q2 2026.
  • BlackRock bought 720,095 ArriVent BioPharma shares in Q2 2026, an estimated $21.3M.
  • ArriVent BioPharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2156 holding.
  • BlackRock first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.